学位論文内容の要旨
博士の専攻分野の名称

博士（医 学）氏 名 増子 和尚

学 位 論 文 題 名Studies on induction of effective anti-tumor immunity and regulatory mechanisms
by novel long peptide vaccination(新規人工合成ロングペプチドによる効率的な抗腫瘍免疫誘導と作用機序に関する研究)
Background and Objectives：Since the discovery of tumor antigens by T. Boon, many investigators
have performed clinical trials of vaccine therapy using peptides from the antigens to activate
tumor-specific cytotoxic T lymphocyte (CTL) in cancer patients. Such vaccines have been thought toinduce tumor specific immune responses to eradicate cancers with superior specificity and safety ascompared to other anticancer drugs. However, the therapeutic efficacy of cancer vaccine therapy
using short MHC class I binding CTL epitopes was limited to induce complete regression. It has
been reported that short peptide vaccine induces defect of Type I helper T (Th1) cell activation andtolerance. To overcome the limited antitumor effect, it is needed to induce fully activated tumor
specific CTL, which can eradicate tumor cells and induce a complete cure in tumor bearing hosts.
Recently, we have demonstrated a critical role of Th1 immunity for inducing fully activatedantitumor CTL, which are essential for eradicating the tumor mass. Moreover, synthetic longpeptides (SLP) that simply extend class I peptide epitopes exhibited superior vaccine efficacy
compared with short peptides. Thus, the existence of Th epitope peptide and the length of SLP
appeared to be key factors for designing therapeutic peptide vaccine. In this study, we havedeveloped an innovative peptide vaccine, referred to as helper/killer-hybrid epitope long peptide(H/K-HELP) by conjugating Th and CTL epitopes of OVA model tumor antigen with glycine linker.
Methods ： We synthesized OVA-H/K-HELP (SIINFEKLGGGGGISQAVHAAHAEINEAGR),
OVA257-264 CTL epitope (class I short peptide), OVA323-339 Th epitope (class II short peptide),
OVA241-270 CTL epitope (class I long peptide) and OVA317-346 Th epitope (class II long peptide) todemonstrate antitumor activity and regulatory mechanism in a mouse tumor-bearing model. We
demonstrated therapeutic activity against tumor by H/K-HELP vaccination with CpG-ODN in themodel using OVA-expressing EG7 tumor cells. To discuss the mechanism of antitumor effect by
H/K-HELP, C57BL/6 mice were vaccinated with short peptides, long peptides or OVA-H/K-HELP
plus CpG-ODN adjuvant and measured OVA-tetramer positive CTL or IFN- producing CD8+ CTL
and CD4+ Th1 cells by ELISA and FACS analysis. Also, cytotoxicity against EG7 was measured by51
Cr release assay. To test which cell subsets presented OVA peptide in vivo, we co-cultured subsets
isolated from the vaccinated mice and CFSE-labeled OT-I CD8+ cells. Moreover, to examine
duration of antigen presentation in vivo, we injected CFSE-labeled OT-I CD8+ T cells or OT-II CD4+
T cells into the mice various days after immunization. The antigen presenting capability of APC
subsets were determined by proliferation of CSFE-labeled OT-I CD8+ T cells or OT-II CD4+ T cells
on FACS analysis. Moreover, we determined whether substitution of the glycine linker to proline oralanine peptide linker impacts vaccine efficacy.
Results: In the EG7 tumor bearing mouse model, OVA-H/K-HELP induced rejection of EG-7 tumor
cells as effectively as the long peptides-Mix (class I long peptide plus class II long peptide), but notclass I short peptide, short peptides-Mix (class I short peptide plus class II short peptide) or class I

long peptide. OVA specific CTL were induced by long peptides-Mix or OVA-H/K-HELP vaccinationcompared with class I long peptide vaccination in the tetramer assay. OVA-H/K-HELP vaccinationinduced IFN- producing OVA specific CTL and Th1 cells by re-stimulation with class I and class IIshort peptide. Also, percentage of cytotoxicity against EG7 was increased by class I long peptide or
OVA-H/K-HELP vaccination. However, total cell numbers of antigen-specific CTL were superior
OVA-H/K-HELP to class I long peptide vaccination. OVA-H/K-HELP vaccination resulted insustained antigen presentation in the inflamed draining lymph node (dLN) by dendritic cells (DC),which triggered the proliferation of CD8+ OT-I T cells and CD4+ OT-II T cells until 60 days aftervaccination. Moreover, glycine-linkered OVA-H/K-HELP exhibited superior antitumor activity
compared with proline- or alanine-linkered OVA-H/K-HELP.
Discussion: In this study, we synthesized a 30 amino acid OVA-H/K-HELP of the model tumor
antigen OVA and addressed the underlying mechanisms for the efficacy of the H/K-HELP vaccine.
We demonstrated that vaccination of mice with OVA-H/K-HELP combined with CpG-ODN resulted
in the sustained antigen presentation by DC in the dLN and potently activated IFN- -producing CTL
and Th1 cells. Moreover, OVA-H/K-HELP vaccination with CpG-ODN indicated marked preventive
and therapeutic effects against tumor. Indeed, therapeutic cancer vaccination with OVA-H/K-HELP
plus CpG-ODN caused complete eradication of OVA-expressing tumors in 80% of mice. Moreover,
OVA-H/K-HELP exhibited stronger antitumor activity compared with recently developed extended
class I long peptide consisted of 30 amino acid. We demonstrated that OVA-H/K-HELP and long
peptides-Mix were able to induce higher numbers of OVA-tetramer+ CTL and superior therapeuticefficacy compared with short peptides-Mix or class I long peptide. Also, the class I long peptide
induced a higher percentage of CTL and antitumor therapeutic activity than class I short peptide andshort peptides-Mix, but exhibited lower antitumor activity compared with OVA-H/K-HELP. Thesefindings suggested that the peptide length, glycine linker, and conjugation of both helper and killer
epitopes were critical for the superior therapeutic vaccine efficacy of OVA-H/K-HELP.
Conclusion: In view of previous works, it is need for novel strategy to develop peptide vaccine
therapy for cancer patients. In this study, we designed H/K-HELP, which was conjugated Th andCTL epitopes with glycine linker to activate both CD4+ T and CD8+ T cells. We have alreadydemonstrated that the tumor antigen-specific immune responses were induced in cancer patients aftervaccination with MAGE-A4- and Survivin-H/K-HELP in our clinical trial. Here, we evaluated themechanisms of H/K-HELP vaccination by using a tumor-bearing mouse model. EG-7 tumor waseradicated by H/K-HELP but not short peptides-Mix vaccination with CpG-ODN adjuvant.
H/K-HELP was presented by only professional DC in dLN and exhibited long lasting antigenpresentation. Moreover, H/K-HELP exhibited stronger antitumor activity as effectively as the long
peptides-Mix compared with the extended class I long peptide. In addition, it was confirmed that
antigen-specific immunity was different from a kind of amino acids in the linker region. Theseresults indicate that peptide length, type of linkers, and combination of CTL and Th epitopes are
critical for inducing strong antitumor effects in vivo. Thus, the present design of H/K-HELP vaccine
would contribute to develop promising strategies for cancer patients.